{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'The investigator is responsible for ensuring that all adverse events observed by the', \"investigator or reported by patient are properly captured in the patients' medical records\", '(source data).', 'The following adverse event attributes must be assigned by the investigator:', 'Adverse event diagnosis or syndrome(s), preferably as term, if known, otherwise if not', 'known signs or symptoms', 'Event description (with detail appropriate to the event)', 'Date of onset (if applicable, date of becoming serious)', 'Date of resolution', 'Seriousness (yes/no) / seriousness criterion (in case of AE fulfils criteria of SAE, SAE', 'reporting is required)', 'Treatment required', 'None', 'Drug Treatment', 'Intensive Care', 'Other', 'Severity (Grade according to CTCAE version 5 or if not specified in CTCAE as follows):', 'Grade I: mild (awareness of sign, symptom, or event, usually transient, requiring', 'no special treatment and generally not interfering with usual daily activities)', 'Grade II: moderate (discomfort that causes interference with usual activities;', 'usually ameliorated by basic therapeutic maneuvers)', 'Grade III: severe (incapacitating with inability to do usual activities or', 'significantly affects clinical status and warrants intervention. Hospitalization', 'may or may not be required)', 'Grade IV: life-threatening (immediate risk of death; requires hospitalization and', 'clinical intervention)', 'Grad V: death)', 'Assessment of relatedness to study treatment (related/not related)', 'Outcome:', 'Recovered/resolved', 'Recovering/resolving/ongoing', 'Recovered/resolved with sequelae', 'Not recovered/not resolved', 'Fatal', 'Unknown (only applicable if patient is lost to follow-up)', 'Confidential', 'Page 54 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Action taken regarding study drugs:', 'None', 'Dose reduced (new dose)', 'Dose increased', 'Temporarily discontinued (stop date, date of re-start)', 'Permanently discontinued (stop date)', 'Not applicable', 'Unknown.', 'Medically significant adverse events considered related to the investigational product by the', 'investigator, coordinating investigator or the Sponsor will be followed until resolved or', 'considered stable.', \"It will be left to the investigator's clinical judgment to determine whether an adverse event is\", \"related or of sufficient severity to require the subject's removal from treatment or from the\", 'study. A subject may also voluntarily withdraw from treatment due to what he or she perceives', 'as an intolerable adverse event. If either of these situations arises, the subject should be', 'strongly encouraged to undergo an end-of-treatment (EOT) assessment and be under medical', 'supervision until symptoms cease or the condition becomes stable.', 'All clinical adverse events (AEs) encountered during the clinical study will be reported on the', 'AE page of the eCRF.', 'Intensity of adverse events will be graded using the National Cancer Institute Common', 'Terminology Criteria for Adverse Events (CTCAE), version 5 (Appendix 2 2).', 'Progression or deterioration of the malignancy under study (including new metastatic lesions', 'and death due to disease progression) will be part of the efficacy assessment and should NOT', 'be reported as AE or SAE.', '6.2.1.3 Laboratory Test Abnormalities', 'Laboratory test results will be recorded on the laboratory results pages of the eCRF. Laboratory', 'test value abnormalities as such should be considered as an AE in case they are:', 'Accompanied by clinical symptoms.', 'Leading to a change in study medication (e.g. dose modification, interruption or', 'permanent discontinuation).', 'Requiring a change in concomitant therapy (e.g. addition of, interruption of,', 'discontinuation of, or any other change in a concomitant medication, therapy or', 'treatment).', \"In general, it is the investigator's responsibility to review all abnormal laboratory results and to\", 'determine if a given value represents a clinically significant change compared to previously', 'obtained values and results in an adverse event (AE) or not.', 'Confidential', 'Page 55 of 79']\n\n###\n\n", "completion": "END"}